Micropime T Injection (Cefepime+ Tazobactam Sodium)

• Composition :
  Cefepime 1 g/ 250 mg + Tazobactam Sodium 125 mg/ 62.5 mg injection.
• Indications :
  For the treatment of uncomplicated and complicated UTI, uncomplicated skin and skin structure infections, and complicated intra-abdominal infections; Additional indication LRTI including pneumonia & Bronchitis; septicaemia; empiric treatment in febrile neutropenic patients.
• Pharmacodynamics :
  Cefepime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Tazobactam generally acts as an irreversible inhibitor and inactivates both plasmid- and chromosomally-mediated beta-lactamases. The combination of cefepime with tazobactam is useful for the treatment of infections due to ESBL-producing organisms. Tazobactam augments and protects the action of cefepime.
• Dosage and administration :
  Maximum adult dose of cefepime should not exceed 6 g a day. Pediatric (2 months to 16 years of age): The usual recommended dosage in pediatric patients up to 40 kg in weight for uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, and pneumonia is 50 mg per kg per dose, administered every 12 hours (50 mg per kg per dose, every 8 hours for febrile neutropenic patients).
• Contraindications :
  Cefepime and tazobactam combination is contraindicated in patients who are hypersensitive to the drugs or other cephalosporins and should be used with caution in patients with a history of hypersensitivity to penicillins.
• Precautions and warnings :
  Before therapy with cefepime and tazobactam for infection is instituted, careful inquiry should be made to determine whether the patient has had previous immediate hypersensitivity reaction to cefepime, cephalosporin, penicillins or other drugs. Clostridium difficile associated diarrhoea (CDAD) has been reported with use of nearly all antibacterial agents, including Cefepime.
• Use in pregnancy, lactation & pediatrics :
  Should be used during pregnancy only when clearly indicated. Cefepime is excreted in human breast milk in very low concentration following parenteral administration and the drug should be used with caution in nursing mothers. The safety and effectiveness of cefepime is not established in the age group <2 months.
• Drug interactions :
  Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with cefepime/tazobactam.
• Adverse reactions :
  The most commonly reported adverse events Local reactions: including phlebitis, pain and / or inflammation, rash, diarrhoea, headache, fever, nausea, pruritus and vomiting.
• Therapy Area :
  Anti-Bacterials